Last Updated: 13 Nov 2024
Executive Summary
Bio-Rad Laboratories Inc. (BIO) is a leading provider of products for life science research and clinical diagnostics. The company has a strong financial position with a market capitalization of $10.07 billion and an EBITDA of $483.49 million. However, the company's EPS is currently negative at -$28.06. Analysts have a mixed outlook on the stock, with three rating it a "Buy" and four rating it a "Hold." The latest stock price is $364.53.
Company Overview
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company's products are used in a variety of applications, including proteomics, genomics, cell biology, and immunology. Bio-Rad is headquartered in Hercules, California and has operations in over 100 countries.
Fundamental Analysis
Bio-Rad Laboratories has a strong financial position with a market capitalization of $10.07 billion and an EBITDA of $483.49 million. However, the company's EPS is currently negative at -$28.06. The company's revenue has grown by 0.028% year-over-year to $2.58 billion. The company's gross profit margin is 60.79%, and its operating margin is 9.94%. Bio-Rad's return on assets is 1.86%, and its return on equity is -9.79%.
Technical Analysis
Bio-Rad Laboratories' stock price has been trading in a range between $262.12 and $387.99 over the past 52 weeks. The stock is currently trading at $364.53, which is above its 50-day moving average of $338.47 and its 200-day moving average of $316.67. The stock's relative strength index (RSI) is 54.47, which indicates that the stock is neither overbought nor oversold.
Short Term Outlook
Bio-Rad Laboratories' stock price is expected to continue to trade in a range in the short term. The stock is currently trading above its 50-day and 200-day moving averages, which is a bullish sign. However, the stock's RSI is neutral, which indicates that there is no clear trend in the stock price.
Long Term Outlook
Bio-Rad Laboratories' stock price is expected to rise in the long term. The company has a strong financial position and a growing revenue stream. The company's products are used in a variety of applications, which gives the company a wide moat.
Analyst Recommendations
Analysts have a mixed outlook on Bio-Rad Laboratories' stock. Three analysts rate the stock a "Buy" and four analysts rate the stock a "Hold." The average analyst target price is $397.33.
